Automakers get one-month reprieve from Trump tariffs

ARCA News Desk

| March 11, 2025
Credit: The White House / Ford
TL;DR
  • Trump grants one-month exemption from new tariffs on vehicle and auto part imports from Canada and Mexico.

  • The decision temporarily shields automakers from 25% tariffs that critics have warned could disrupt supply chains and raise vehicle prices.

President Donald Trump has granted automakers a one-month exemption from new tariffs on vehicle and auto part imports from Canada and Mexico. The decision provides temporarily relief to automotive manufacturers who had been bracing for increased costs.

What prompted the deferment: Trump’s decision exempts the auto industry—at least for now—from the 25% across-the-board tariffs he has imposed on imports from Canada and Mexico. Automakers have warned that the tariffs could significantly disrupt supply chains, increase vehicle prices, and negatively impact American consumers.

Playing for time: The exemption gives auto companies more time to adjust operations and explore ways to mitigate the impact. It follows mounting pressure from industry leaders, lawmakers, and trade groups who argued that the tariffs would hurt American jobs and raise car prices by as much as $3,000 to $12,000 per vehicle.

Longer-term exemptions floated: The North American auto supply chain is highly integrated, with many parts crossing borders multiple times during production. The exemption allows manufacturers to navigate these complexities without immediate financial strain. Commerce Secretary Howard Lutnick indicated that automakers adhering to the United States-Mexico-Canada Agreement (USMCA) rules of origin may receive further tariff relief beyond the one-month exemption, especially if they commit to U.S. investments.

Other manufacturers respond: Across the broader manufacturing sector, Trump has encouraged major players to onshore production to avoid tariffs, and many have said they will heed the call, including ABB which has announced a $120 million expansion of its American production capabilities. Drug giant Pfizer has said it is considering relocating its overseas manufacturing to existing U.S. facilities.

Skip to content